不同的新辅助化疗方法对宫颈癌患者治疗效果及生存期的影响

摘要

Objective To analyze and discuss the effect of neoadjuvant chemotherapy combined with radiotherapy on the efficacy and survival time of patients with cervical cancer.Methods We selected 119 patients with cervical cancer and assigned them into 4 groups according to different new auxiliary methods adopted.Group A (31 cases)received surgical treatment directly,group B (32 cases)neo-adjuvant chemotherapy,group C (29 cases)neoadjuvant intra-arterial infusion combined with intravenous chemotherapy,and group D (27 cases)neoadjuvant chemotherapy combined with intracavitary brachytherapy.Efficacies of neoadjuvant therapy in each group were observed and compared,together with the analysis of postoperative auxiliary treatment,risk factors and prognosis.Results The results showed that among 88 cases with neoadjuvant therapy there was no worsening condition and in group B,the clinical efficacy was 50.0%,significantly lower than that in group C (79.3%)and in group D (81.5%,P <0.05).There was no significant difference in clinical efficacy rate between group C and group D (P >0.05).Among 119 patients 57 cases received postoperative adjuvant therapy and more patients in group A received postoperative adjuvant treatment compared with group B,group C and group D.The differences were statistically significant(P <0.05).There were no significant difference in postoperative adjuvant treatment among group B,group C and group D (P >0.05).Conclusions Neoadjuvant therapy can effectively improve the clinical therapeutic effect;and compared with neoadjuvant chemotherapy neoadjuvant intravenous and arterial chemotherapy and neoadjuvant chemotherapy combined with intra-cavitary radiotherapy can improve the clinical curative effect among patients.%目的：分析新辅助静脉化疗、动静脉联合化疗及静脉化疗联合腔内放疗对宫颈癌患者治疗效果及生存期的影响。方法选取119例宫颈癌患者，根据临床上对患者所使用不同的的新辅助方法将所有患者分为甲、乙、丙、丁4组，其中甲组患者31例采用直接手术治疗，乙组患者32例采用新辅助静脉化疗，丙组患者29例采用新辅助动脉静脉联合化疗，丁组患者27例则采用新辅助静脉化疗联合腔内放疗。观察比较各组患者新辅助治疗效果，分析各组患者的术后辅助治疗状况、术后病理危险因素以及治疗预后等。结果对乙丙丁三组88例运用新辅助治疗的患者中，没有病情进展患者出现，另外乙组患者的临床有效率为50．0％，显著低于丙组患者的79．3％以及丁组患者的81．5％（均 P ＜0．05），而丙组患者和丁组患者的临床有效率比较差异无统计学意义（P ＞0．05）；119例患者中57例患者接受了术后辅助治疗，并且甲组接受术后辅助治疗的患者显著多于乙组、丙组、丁组，数据比较差异有统计学意义（P ＜0．05），乙丙丁三组患者中相互之间比较接受术后辅助治疗的数据比较差异无统计学意义（均 P ＞0．05）。结论对患者运用新辅助治疗能够有效提高患者的临床治疗效果，且与新辅助静脉化疗比较，新辅助动静脉联合化疗和新辅助静脉化疗联合腔内放疗能够更好地提高患者的临床疗效。